TL1A as a therapeutic renaissance in inflammatory bowel disease: a systematic review from molecular mechanisms to clinical translation - PubMed
3 hours ago
- #TL1A therapy
- #inflammatory bowel disease
- #precision medicine
- TL1A inhibitors are a promising new therapy for inflammatory bowel disease (IBD), addressing inadequate responses to existing treatments.
- TL1A-DR3 signaling drives inflammation, fibrosis, and gut barrier dysfunction, key issues in IBD progression.
- Phase 2 trials of anti-TL1A antibodies like Tulisokibart showed clinical remission rates of 26-66% in moderate-to-severe IBD with good safety.
- These drugs offer potential anti-fibrotic effects and benefits for treatment-refractory patients, supporting precision medicine approaches in IBD care.